To read the full article sign up for free or sign in.

Junshi taps Revitope in discovery stage to develop antibody-based cancer immunotherapies

July 14, 2020

BEIJING – Besides advancing its neutralizing antibodies for COVID-19, Shanghai Junshi Biosciences Co. Ltd. is aiming to expand its pipeline. On July 13, it entered a collaboration with Revitope Oncology Inc.

BioWorld BioWorld Asia Deals and M&A China

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 21, 2025.

Neurobiogen divulges new MAO-B inhibitors for Parkinson’s disease

BioWorld Science

Neurobiogen Co Ltd. has synthesized monoamine oxidase-B (MAO-B) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Scorpion Therapeutics patents p53 Y220 mutant activators

BioWorld Science

Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the...

Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

BioWorld

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...